Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Takuo Matsukawa
Observed names:
M. Takuo,
TAKUO MATSUKAWA
Institutions:
University of Occupational and Environmental Health Japan,
University of Rochester Medicine
Observed institutions:
University of Occupational and Environmental Health Japan,
University of Rochester Medicine,
University of Rochester
ORCID:
0009-0009-4418-399X
Observed ORCID:
0009-0009-4418-399X
OpenAlex ID:
A5010953950
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer
2020
·
Satoshi Endo
, Hiroaki Oguri
, et al.
·
Journal of Medicinal Chemistry
·
67
Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World
2023
·
AKINORI MINATO
, RIEKO KIMURO
, et al.
·
Anticancer Research
·
36
PDF
Targeting Nrf2-antioxidant signalling reverses acquired cabazitaxel resistance in prostate cancer cells
2021
·
Satoshi Endo
, Mina Kawai
, et al.
·
The Journal of Biochemistry
·
27
Latrophilins as Downstream Effectors of Androgen Receptors including a Splice Variant, AR-V7, Induce Prostate Cancer Progression
2024
·
Yuki Teramoto
, Mohammad Amin Elahi Najafi
, et al.
·
International Journal of Molecular Sciences
·
9
ANGPTL8 links inflammation and poor differentiation, which are characteristics of malignant renal cell carcinoma
2022
·
Takuo Matsukawa
, Tomomitsu Doi
, et al.
·
Cancer Science
·
9
PDF
Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer
2021
·
NAOHIRO FUJIMOTO
, MASAKI SHIOTA
, et al.
·
In Vivo
·
9
PDF
Protective role of mineralocorticoid receptor signaling in urothelial tumorigenesis.
2023
·
Yujiro Nagata
, Takuo Matsukawa
, et al.
·
PubMed Central
·
8
PDF
GULP1 as a Downstream Effector of the Estrogen Receptor-β Modulates Cisplatin Sensitivity in Bladder Cancer
2024
·
TOMOYUKI TATENUMA
, TAKUO MATSUKAWA
, et al.
·
Cancer Genomics & Proteomics
·
7
PDF
Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer
2022
·
YUJIRO NAGATA
, TAKUO MATSUKAWA
, et al.
·
Anticancer Research
·
7
Recent advances in understanding the role of sex hormone receptors in urothelial cancer
2025
·
MOHAMMAD AMIN ELAHI NAJAFI
, TAKUO MATSUKAWA
, et al.
·
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
·
5
PDF
Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer
2022
·
YUJIRO NAGATA
, TAKUO MATSUKAWA
, et al.
·
Anticancer Research
·
5
PDF
Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy
2026
·
AKINORI MINATO
, KAZUMASA JOJIMA
, et al.
·
Cancer Diagnosis & Prognosis
·
4
PDF
Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma
2025
·
Akinori Minato
, Tomohisa Takaba
, et al.
·
Japanese Journal of Clinical Oncology
·
4
Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience
2025
·
AKINORI MINATO
, YUI MIZUSHIMA
, et al.
·
In Vivo
·
3
PDF
PGC1α as a downstream effector of KDM5B promotes the progression of androgen receptor-positive and androgen receptor-negative prostate cancers
2024
·
Yuki Teramoto
, Zhiming Yang
, et al.
·
American Journal of Cancer Research
·
3
PDF
Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer
2023
·
YUJIRO NAGATA
, KAZUMASA JOJIMA
, et al.
·
Anticancer Research
·
3
PDF
Visfatin Promotes Renal Cell Carcinoma Progression: Evidence from Clinical Samples and Cell Line Models
2025
·
Eiji Kashiwagi
, Miho Ushijima
, et al.
·
Journal of Kidney Cancer and VHL
·
2
PDF
Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide
2025
·
YUJIRO NAGATA
, TAKAOMI SUGI
, et al.
·
In Vivo
·
2
PDF
Immune Checkpoint Inhibitor Retreatment after Enfortumab Vedotin in Advanced Urothelial Carcinoma: A Descriptive Study with Exploratory Evaluation of Radiotherapy
2026
·
Akinori Minato
, Yoshihiro Sugita
, et al.
·
JMA Journal
·
1
Reduced Uncoupling Protein 1 Expression in Periprostatic Adipose Tissue and Its Association With Higher Prostate Cancer Grade
2026
·
Eiji Kashiwagi
, Miho Ushijima
, et al.
·
International Journal of Urology
·
1
Expression of Glucocorticoid Receptor and FOXO1/phospho-FOXO1 in Bladder Cancer as Independent Prognosticators
2025
·
HIROKI IDE
, MOHAMMAD AMIN ELAHI NAJAFI
, et al.
·
Cancer Genomics & Proteomics
·
1
Pioglitazone Suppresses Urothelial Tumorigenesis In Vitro: A Potential Chemopreventive Agent
2025
·
NGUYEN THU QUYNH
, YUJIRO NAGATA
, et al.
·
Cancer Genomics & Proteomics
·
1
PDF
MP65-14 THE IMPACT OF GULP1 AS A DOWNSTREAM EFFECTOR OF THE ESTROGEN RECEPTOR-β ON MODULATING CISPLATIN SENSITIVITY IN BLADDER CANCER
2024
·
Tomoyuki Tatenuma
, Takuo Matsukawa
, et al.
·
The Journal of Urology
·
1
PDF
Impact of Adjuvant Chemotherapy After Radical Cystectomy for Patients With Locally Advanced Bladder Cancer
2023
·
Akinori Minato
, Ikko Tomisaki
, et al.
·
The Japanese Journal of Urology
·
1
PDF
Real-world Outcomes of First-line Platinum-based Chemotherapy in Patients Aged 80 Years or Older With Metastatic Urothelial Carcinoma
2026
·
AKINORI MINATO
, KAZUMASA JOJIMA
, et al.
·
Cancer Diagnosis & Prognosis
PDF
Show more works
View as search
Works count:
30
Citation count:
216
H-index:
7
I10-index:
3
Year
Topic
Type